Brain Research Bulletin
October 6, 2026
Ziyi Hua, Yongqiang Shu, Li Li et al.
INTRODUCTION: This study investigated changes in multiband amplitude of low-frequency fluctuations in patients with major depressive disorder following a 2-week combination treatment regimen of esketamine and sertraline, and examined the associations between ALFF changes and clinical symptom improvement. METHODS: Forty patients with major depressive disorder (MDD) received esketamine (0.25...
BMC Psychiatry
August 5, 2026
Xiang Liu, Yuanzhi He, Lifeng Li et al.
Abstract Introduction Major depressive disorder (MDD) is characterized by dysfunction in higher-order cortical regions involved in emotional and cognitive processes; however, its neurobiological basis remains unclear. Pharmacological treatments, including esketamine and sertraline, produce rapid antidepressant effects. We investigated the local intrinsic neural dynamics underlying these...
Brain Research Bulletin
November 13, 2025
Xiang Liu, Ziyi Hua, Yongqiang Shu et al.
1 citation
This study aims to explore the relationship between the antidepressant effects of drugs (esketamine combined with sertraline) and brain function changes in patients with major depressive disorder. A total of 27 patients with major depressive disorder (MDD) and 27 healthy individuals were included in the study. All MDD patients received a 2-week course of intravenous esketamine infusion (0.25...
Journal of Affective Disorders
September 1, 2025
Xianghong Liu, Lifeng Li, Haijun Li et al.
INTRODUCTION Dysfunction in amygdala networks has been implicated in major depressive disorder (MDD). Pharmacological treatments, such as esketamine and sertraline, are believed to exert their antidepressant effects by modulating amygdalar activity. This study aimed to investigate the relationship between changes in dynamic functional connectivity (dFC) within amygdala subregions and treatment...
Neuroscience
July 8, 2025
Xiang Liu, Yumeng Liu, Jun Tu et al.
2 citations
We aimed to investigate the relationship between changes in resting-state functional connectivity in a subregion of the hippocampus and the antidepressant effects of esketamine as well as to identify potential neuroimaging markers of the treatment outcomes. Twenty-nine patients with major depressive disorder (MDD) received six intravenous infusions of esketamine. All patients completed the...
Journal of Affective Disorders
March 1, 2025
Xiang Liu, Zhipeng Wei, Lifeng Li et al.
12 citations
Esketamine has demonstrated acute antidepressant effects in patients with major depressive disorder (MDD). This study investigated whether these effects associate with reversible white matter fiber integrity recovery using diffusion imaging. Twenty patients with MDD and 20 healthy controls received 2-week esketamine treatment. Patients received 0.25 mg/kg intravenous esketamine. Emotional and...
Frontiers in Neurology
June 13, 2018
Liting Chen, Xiaole Fan, Haijun Li et al.
Impaired spontaneous regional activity and altered topology of the brain network have been observed in obstructive sleep apnea (OSA). However, the mechanisms of disrupted functional connectivity (FC) and topological reorganization of the default mode network (DMN) in patients with OSA remain largely unknown. We explored whether the FC is altered within the DMN and examined topological changes...